Close Menu

CHICAGO (GenomeWeb) – Two next-generation precision oncology drugs, one an EGFR inhibitor and an ALK inhibitor, have shown to be far more effective against advanced non-small cell lung cancer than older drugs in their class.

At the American Society of Clinical Oncology's annual meeting, researchers presented data from two head-to-head NSCLC trials, one comparing the first targeted EGFR inhibitor Iressa (gefitinib) against the next-generation dacomitinib; and another comparing the first ALK-inhibitor Xalkori (crizotinib) against newer agent Alecensa (alectinib).

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.